Cargando…

A tetravalent dengue nanoparticle stimulates antibody production in mice

BACKGROUND: Dengue is a major public health problem worldwide, especially in the tropical and subtropical regions of the world. Infection with a single Dengue virus (DENV) serotype causes a mild, self-limiting febrile illness called dengue fever. However, a subset of patients experiencing secondary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva, Elisângela F, Orsi, Mariana, Andrade, Ângela L, Domingues, Rosana Z, Silva, Breno M, de Araújo, Helena RC, Pimenta, Paulo FP, Diamond, Michael S, Rocha, Eliseu SO, Kroon, Erna G, Malaquias, Luiz CC, Coelho, Luiz FL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349613/ https://www.ncbi.nlm.nih.gov/pubmed/22439913 http://dx.doi.org/10.1186/1477-3155-10-13

Ejemplares similares

Dengue Virus 2 American-Asian Genotype Identified during the 2006/2007 Outbreak in Piauí, Brazil Reveals a Caribbean Route of Introduction and Dissemination of Dengue Virus in Brazil
por: Barcelos Figueiredo, Leandra, et al.
Publicado: (2014)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Phylogenetic analysis of Dengue virus 1 isolated from South Minas Gerais, Brazil
por: Drumond, Betania Paiva, et al.
Publicado: (2016)

Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice
por: Versiani, Alice F., et al.
Publicado: (2017)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties
por: Kim, Mi Young, et al.
Publicado: (2018)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Nitric oxide synthase expression correlates with death in an experimental mouse model of dengue with CNS involvement
por: de Souza, Kátia Paulino Ribeiro, et al.
Publicado: (2013)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
por: Basheer, Amina, et al.
Publicado: (2023)

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine
por: Tsuji, Isamu, et al.
Publicado: (2021)

Long-term protection against dengue viruses in mice conferred by a tetravalent DNA vaccine candidate
por: Wang, Ran, et al.
Publicado: (2020)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

A case-control study to determine the effectiveness of a tetravalent dengue vaccine in the state of Paraná, Brazil
por: de Moraes, José Cássio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k5o71o1ukpel07ekjfs93to765